OBJECTIVES: The Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing the new Patient Reported Impact of Dermatological Diseases (PRIDD) measure, a patient-reported outcome measure of the impact of dermatological conditions on the patient’s life. We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritise for inclusion in PRIDD. The aim of this study is to examine the impacts ranked as most important to European dermatology patients and explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group).

METHODS: The Delphi survey consisted of two rounds. Adults (≥ 18 years) living with a dermatological condition were recruited through the International Alliance of Dermatology Patient Organizations’ membership network. The survey consisted of a demographics questionnaire and 263 impact items and was available in six languages. Quantitative data were collected using Likert-type ranking scales and analysed against a priori consensus criteria. Qualitative data were collected using free-text responses and a Framework analysis was conducted. European data were obtained, and descriptive statistics, including multiple subgroup analyses, were performed.

RESULTS: 441 people representing 46 dermatological conditions from 25 European countries participated. The results produced a list of the top 20 impacts on European patients, with psychological impacts accounting for the greatest proportion. Further subgroup analyses are currently underway.

CONCLUSIONS: This study has identified what patients from Europe consider to be the most important issues impacting their lives. The data support previous evidence that patients experience profound psychological impacts and require psychological support. The findings can inform research, clinical practice, and policy by indicating research questions and initiatives that are of most benefit to patients.